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Abstract
This thesis develops an approach to enhance drug delivery to bone tumors by
implementing a non-invasive mechanical loading technique. An imaging protocol that
characterizes the load-enhanced drug uptake is also presented. The long-term goal of this work is
to develop a clinical protocol that enhances the delivery of therapeutic agents to bone tumors by
utilizing load-bearing activity. This easy-to-implement approach could help increase drug uptake
into the tumor interstitial fluid space as well as into tumor cells, thereby enhancing a drug’s
clinical effect while decreasing systemic drug dosage and unwanted side effects. This thesis
details the process used to grow cancer cells, induce tumors in a rat model, measure tumor
development, inject a radioactive tracer, apply mechanical loading non-invasively, and image
and quantify drug uptake distribution in bone tumors. Assessment of 99mTc-labeled pamidronate
uptake was completed in vivo using planar microSPECT (2D gamma camera scans) employing a
rat model of bone metastases. The pilot study using this methodology demonstrated that noninvasive mechanical loading enhanced drug delivery to cancerous tibial tumors by 34% when
compared to contralateral non-loaded, non-tumor bearing tibiae. Several improvements to this
approach have been developed including 1) improved cancer cell viability after injection, 2)
enhancement of cancer cell inoculation by arthrotomy surgery instead of direct tibial injection, 3)
shifting from gamma camera to 3D microPET imaging, 4) use of tumor-bearing tibiae as
controls, 5) use of the clinically relevant Herceptin as the injected drug, and 6) implementation
of high-resolution microCT and histology to assess bone destruction from tumor growth. If
additional studies in the rat model using these improved techniques demonstrate load-induced
enhancement of drug delivery, the approach will be attempted in the clinic. Clinical studies will
implement exercise and/or non-invasive mechanical activity to enhance drug delivery. If
successful, this approach would result in an improvement in the quality of life of patients
suffering from bone cancer.
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Chapter 1 Introduction, Background and Significance
1.1 Introduction to project
The side effects caused by chemotherapy in patients suffering from cancer are directly
related to the body’s systemic drug concentration. The physical side effects experienced by
patients add to psychological damage that can further affect the patient’s quality of life. Many
approaches have been explored in cancer research to increase tumor drug concentration to
increase a drug’s therapeutic effects so that systemic drug dosage and unwanted side effects can
be reduced. The objective of this work is to target bone cancers and improve local drug uptake
into tumor cells and their environment. This thesis project utilizes the well-established skeletal
tissue deformation induced fluid flow phenomenon as a technique to initiate pressure gradients
within bone to enhance drug delivery.
Three main mechanisms that may be responsible for enhanced drug delivery to bone
tumors by mechanical loading are: 1) deformation of bone tissue creates pressure differences that
drive fluid flow within bone and within the marrow cavity. These flow streams might create
interstitial fluid currents towards the tumor and improve convective delivery; 2) formation of
hydrostatic pressure within the marrow cavity could overcome the high pressure within the
tumor, creating radial flow towards the tumor center; and 3) mechanical loading could deform
blood vessels near the tumor and create increased fluid filtration. Implementing load-bearing
activity may be a simple, efficacious approach to enhance drug delivery to bone tumors, thereby
decreasing unwanted side effects and increasing a patient’s quality of life.

1.2 Physiological hallmarks of solid tumors
1.2.1 From normal to malignancy: There are more than 100 distinct types of cancer, and
histological subtypes of tumors can be found within affected organs (Hanahan and Weinberg,
2000). Therefore, understanding how tumors develop and behave can provide valuable
information on how to target them and therefore enhance drug efficacy. This broad spectrum of
tumors shows that cancers have common and uncommon occurring physiological hallmarks.
Some common physiological hallmarks of solid tumors include self sufficiency in growth
signals, insensitivity to anti-growth signals, insensitivity to apoptosis signals, increased
replication potential, persistent angiogenesis, and tissue invasion and metastases. Some
5

uncommon physiological hallmarks in cancer include DNA damage/replication stress,
proteotoxic stress, metabolic stress, and oxidative stress (Luo et al., 2009).

1.2.2 Acquired autocrine signaling: Acquired autocrine stimulation and cell membrane
receptor over-formation, driven by dominant oncogene over-expression, allows cancer cells to
reduce their dependency on their environment (Hanahan and Weinberg, 2000). Nonetheless,
tumors are composed of several cell types, such as stromal cells, fibroblasts, and endothelial
cells, which play key roles in tumor growth, stimulation and proliferation (Sheih, 2011).

1.2.3 Anti-growth signal insensitivity: It is known that healthy cells differentiate and
proliferate until they reach a state of homeostasis. However, disruption of the pRb
(retinoblastoma protein) signaling pathway, the pathway where almost all anti-proliferative
signals end up, stimulates cancer cells to change from the normal state of homeostasis to become
antigrowth-signal insensitive (Weinberg, 1995). There are different ways to disrupt the pRb
signaling pathway, including overstimulation by extrinsic factors (Zuscik et al., 1995) and by
pRb hyper-phosphorylation (Lee et al., 1992). Disruption of the intrinsic transcription factors
E2F-pRb complex results in enhanced cell proliferation by enhanced cell division activation
(Chellappan et al., 1991). Furthermore, complete deregulation of the pRb pathway can be caused
by several pRb-gene mutations.
1.2.4 Inactivation of tumor suppressor; preventing apoptosis: A tumor’s capability to
expand is explained by the prevalence of a positive net cell number, the total number of cells
minus dead cells. Apoptosis is driven by intracellular and membrane bound signaling factors that
regulate cell death and survival, maintaining tissue stasis (Hanahan and Weinberg, 2000).
Inactivation of apoptotic soluble signals is explained by the inactivation of tumor suppressor
genes such as p53 (caspases machinery), where p53-deficient mice develop normally but are
susceptible to spontaneous tumors (Donehower et al., 1992). Enhancement of oncogene
expression like myc provokes enhancement of cell division and reduction of cell apoptosis
(Khaira et al., 1998). Enhancement of the myc gene was seen in Khaira et al. (1998), where
amplified translocated c-myc genes were present in lymphoma cell lines. Moreover, hyper-
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activation of membrane bound protein blc-2 blocked cytochrome C release from mitochondria
therefore preventing apoptosis (Yang et al., 1997).

1.2.5 Increased replication potential; immortality: Immortality, or lack of senescence, is
a classic hallmark of cancer cells. Telomeres, the ends of chromosomes, are maintained in
cancer cells, avoiding chromosomal condensation (fusion) and therefore cell apoptosis, in
contrast to healthy cells (Rudolph et al., 1999). There is no telomeric-length developmental
dependence in mice; however, there is a telomeric-length effect on life span, healing power and
hematopoiesis (Rudolph et al., 1999). Up-regulation of telomeric repair enzymes (telomerase)
permits unlimited replication (mitosis) of the next generation’s cancer cells in contrast to
telomerase-deficient mice cells (Collado et al., 2007). Consequently, tumors never grow old.

1.2.6 Sustained angiogenesis and invasion leads to metastases: Driven by the concept of
diffusion, a cell must be located ~100µm from the blood supply to survive. This allows the cell
to obtain sufficient oxygen, nutrition, and an outlet for waste, thus maintaining normal stasis. It
has been shown in a mouse model that in order for cancer cells to continue proliferation,
angiogenesis becomes a vital acquired trait for further tumor growth and development
(Hashizume et al., 2010) (Fig. 1). Mice that received inhibitor for Ang2 and VEGF (angiopoietin
and vascular endothelial growth factors, respectively) presented reduced vascular sprouts and
reduced tumor vascularity and growth, in addition to increased cell death. A tumor’s angiogenic
ability might be caused by abnormal environmental changes, such as necrosis (e.g., lesions or
fracture in normal tissue) or by genetic set-points driven by growth/expansion and cell
differentiation (Shieh, 2011). In cancer, physical stresses and genetic predispositions offsets the
production of pro and/or con signals for angiogenesis. In any case, increased expression of
VEGF and/or FGFs (fibroblast growth factors), or inhibition of thrombospondin-1 and/ or Binterferon offers the tumors the ability to grow blood vessels, expand and acquire new
developmental traits, such as metastases (Hanahan and Weinberg, 2000).
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Figure 1. The process of
angiogenesis is a series of
linked and sequential steps that
ultimately leads to the
development of a vascular
blood supply to the tumor mass.
Tumor cells or host cells
(immune or adjacent normal
tissue cells) secrete angiogenic
growth factors. Cell-cell and
cell-environment interactions
lead to endothelial cell
proliferation, migration, and
invasion. Vessel formation may
be increased by certain stimuli
such as hypoxia, low pH,
cytokines, activated oncogenes,
or loss of tumor suppressor
gene function. From Reinmuth
et al., 2003.

Driven perhaps by an enhanced ability to invade neighboring tissue or by the physical
stress of the environment (matrix stiffness, nutrition levels, cell density, pH levels, necrosis),
malignant cancer cells will eventually detach from the primary colony and move to a distant
location. In metastases, cancer cells become absolutely independent of their environment, which
probably indicates a reverse differentiation step to a level of higher cellular pluripotency,
(epithelial to mesenchymal transition), therefore allowing for cancer cells to accommodate to
new environments (Shieh, 2011). The most notable capability for detachment is the lack of
physical cell-to-cell coupling and cell-to matrix adhesion. Deregulated adhesion molecules
include integrins, CAMs, and cadherins (Hanahan and Weinberg, 2000). The lack of celladhesion coupling is a resultant of bypassing the intracellular anti-growth signaling, which is
downstream of the adhesion signaling pathway, or as a result of under-expression and/or overinhibition of these adhesion complexes (Shieh, 2011).
There are pre-requisites for metastases, and these pre-requisites are the inclusive
physiological hallmarks of cancer (Nguyen and Massague, 2007). Consequently, after
proliferation, invasion, angiogenesis and lost adhesion, the sequential developmental progression
of cancer cells will lead to dissemination and colonization. Dissemination is explain by the
theory of “seed and soil” of compatible tissues and/or within the concept of natural selection and
8

advantageous cell adaptability (Merlo et al., 2006). Colonization might be a genetic
predisposition of cancer cells to metastasize or might be a phenotypic trait gained by cancer cells
in growth and development (Nguyen and Massague, 2007). In conclusion, transformation of
normal cells to malignancy is a multi-step process that includes genetics, phenotypic
transformations, common and infrequent characteristics and unknown causes, yet to be defined.

1.3 Solid tumors and drug delivery
1.3.1 Sequential changes of the tumor phenotype and the effects on drug delivery;
cellularity and tumor density: Over 85% of tumors are solid and they share a physical phenotype.
Solid tumors contain common characteristics that hinder drug delivery. These characteristics
appear sequentially and are set initially by the fast proliferation and increasing cellularity of the
tumor (increased tissue density). The large cell number per unit volume displaces existing
vessels and creates alienated cell populations (Minchinton and Tannock, 2006). Increasing cell
density provokes the collapse of the existing lymphatic vessels, making them non-functional
(Shieh, 2011; Padera et al., 2004). Ultimately, continuous tumor growth will lead to the
establishment of new blood vessels in response to acquired genetic/phenotypic traits and or in
response to the physical stress. The new blood vessels created are asymmetric, more permeable,
and blood flow within them is irregular (Baish et al., 1997) (Fig. 2). As tumor cellularity and
angiogenesis increases, increased extracellular matrix (ECM) production also occurs. This
combined disorganized growing system develops high interstitial pressure, which is a major
factor in convective and diffusive drug delivery.
Figure 2. The natural
hierarchy of blood vessel
formation: a) From arteries
to arterioles to capillaries
to venules and finally to
veins. b) Tumor vessel
formation is abnormal and
irregular, blood flow is
sometimes reversed, and
tissue architecture is
asymmetrical. From Jain
and Stylianopoulos, 2010.
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1.3.2 The tumor vasculature and drug kinetics: In combination with solid tumor physical
traits that hinder drug delivery, systemic drug pharmacokinetics is also an important factor in
drug transport (Minchinton and Tannock, 2006). Drug delivery is characterized by dosage,
plasma metabolism, penetration and distribution homogeneity, effective concentration per
volume, drug specificity and mode of action, retention and clearance (Garattini, 2007). Because
of the drug delivery kinetics, in vivo models of chemotherapy distribution measured by
fluorescence and immuno-histochemistry have shown a heterogeneous delivery with poor uptake
(Minchinton and Tannock, 2006) (Fig. 3 and Fig. 5). Inferior delivery and uptake has been
correlated with increased tumor size, low time of exposure, and seclusion from blood vessels.
Consequently, further tumor development worsens delivery and uptake of therapeutic agents,
decreasing the drug toxicity level, therefore worsening the patient’s prognosis.

Figure 3. Schematic illustrating the gradients in oxygen, nutrients and effectiveness of drug
concentration in a tumor. The supply of a drug to the tissue depends on its dose and pharmacokinetics.
Movement of drug in the interstitial space is hindered by interactions with extracellular and cellular
components. These factors add to the tortuosity and irregularity of blood vessels. Systemic drug
delivery and tissue penetration is determined by the balance among supply, metabolism, penetration,
binding and sequestration. From Minchinton and Tannock, 2006.

The distribution of drugs via tumor vasculature is characterized by the transport across
the vascular wall and then by the transport through the interstitial compartment (Baish et al.,
1997) (Fig. 3). Such transport of molecules of any size, charge and configuration must involve
diffusion and/or convection. Drug delivery in normal and tumor tissue is strongly related to
Fick’s law, Darcy’s law, and Starling’s law of transcapillary flow (Jain, 2001; Heldin et al.,
2004). Transport across the capillary wall is determined by 1) the hydrostatic pressure in the
10

capillary (systolic-diastolic pulse pressure difference), 2) colloid osmotic pressure in the
interstitium (water content driven by the solute concentration difference), 3) the hydraulic
conductivity of the vessel (blood vessel surface area and permeability/leakiness) and 4) the
reflection coefficient (concentration of albumin in the plasma). In addition, the distribution of
drugs is also defined by the vessel geometry (anisotropy, density, length and diameter), blood
cellularity, and flow rate (viscosity), also known as Bernoulli's principle.
Tumors are dynamic, growing systems that affect the pharmacokinetics and
pharmacodynamics of a drug, playing an important role in the spatial and temporal drug
distribution (Jang et al., 2003). A spherical tumor with a diameter less than 2 mm can be
supported by existing tissue vasculature, but further growth will require angiogenesis (Zetter,
1998). This vascular angiogenesis in animal models has been shown to sprout and fully develop
within 10-17 days (Jang et al., 2003). Even though these vessels are formed by healthy
endothelial cells, the fast rate of formation leads to tumor vessels that are leaky as a result of
discontinuities in the endothelium. The spatial and temporal distribution of the blood vessels in
the tumor is such that the veins are primarily located in the central region of the tumor, while the
arterioles are in the periphery. This vascular arrangement can explain the results cited by
Fukumura and Jain (2007) in which the pressure measured is high in the solid tumor center, and
then pressure decreases as it reaches the periphery and suddenly drops once past the tumor
border. The sudden drop of pressure can be mostly attributed to the functional lymphatics outside
the tumor volume.

1.3.3 Increased rate of extracellular matrix production; effects on drug distribution: The
tumor blood flow and the transport into the surrounding tissue can also be affected by the overexpression of ECM molecules, which acts as a barrier that causes drug accumulation and
retention (Fig. 4). The ECM rate of synthesis, ECM composition, ECM architecture and tissue
function are important factors in drug delivery (Jang et al., 2003). Drug affinity to ECM
molecules can modify temporal and spatial drug distribution. An example of ECM involvement
and drug distribution in tumors is the higher production of glycosaminoglycans (hyaluronan and
proteoglycans), which lowers the hydraulic conductivity and thus the convective interstitial flow.
Also, high production of collagen contributes to transport resistance for large molecules like IgG
antibodies. Wiig et al. (2008) provide a great review on the distribution of macromolecules in
11

healthy and diseased tissue. Their description states that the phenomenon of interstitial exclusion
is an obstruction of the interstitial fluid space available for macromolecules, given that two
molecules cannot occupy the same space. These steric exclusions add to the ionic interactions
between drugs and the ECM (Fig. 4).
Figure 4. Schematic of the exclusion
phenomenon in the interstitium. The
interstitial space is divided into two
phases: the interstitial fluid and the
structural molecules. Steric exclusion
results from ECM macromolecular
crowding. Available space for other
molecules diffusing is less, equal or
more than the total interstitial fluid
volume. Charge exclusion, at
physiological pH values, can have high
affinity for the drug being delivered.
Shown are collagens (black and white),
negatively charged proteoglycans (black), small drug (yellow), large drug (dark blue) and positively
charged large drug (light blue). From Wiig et al., 2008.

1.3.4 Drug delivery in tumors: There have been several approaches to enhance the
delivery of high molecular weight compounds, antibodies, micelles, liposomes, nano-particles,
magnetic or charged particles, and other compounds in vivo. Some approaches include
increasing the transmural vessel pressure difference by increasing systemic blood pressure, in
addition to regulating vasculature structure (Fukumura and Jain, 2007), enhancing vessel dilation
and homogeneity for greater blood flow (Fukumura and Jain, 2007), implementing artificial
lymphatics (DiResta et al., 2007), implementing ultrasound as a mechanical wave to enhance
filtration by thermal induced sonoporation (Besic, 2007) and the use of magnetic fields to
improve spatial localization of charged particles (Hui, 2008).
It is important to mention that delivery of even small molecules that are diffusion-driven
can be enhanced by the mixing principle of applied convention. This principle allows for
temporal improvement and enhanced spatial distribution in drug transport.

1.3.5 High tumor interstitial pressure, increased ECM production and sustained
vasculature; effects on drug delivery: An illustration of the consequence of high interstitial
pressure and cell populations distant from the blood supply is the formation of hypoxic cells
(Fukumura and Jain, 2007), which by definition are less affected by radiation therapy, given that
12

they lack available oxygen for production of free radicals. Because cancer cells have defective
nucleotide repair machinery, chemotherapy targets the DNA of fast replicating cells (Ta et al.,
2009). However, hypoxic cells do not proliferate as fast as non-hypoxic cells, which make them
less sensitive to chemotherapeutic agents. Another consequence of increased interstitial pressure
and increased ECM production is an accumulation of metabolic products (Tannock, 2001). These
metabolic products decrease the environmental pH, hampering the functionality of some drugs.
The final outcome of high interstitial pressure in solid tumors is that the net convective flow is
outward from the tumor’s center (Baxter, 1989), preventing effective drug distribution deep into
the tumor (Fig 5).

Figure 5. Section from a mouse mammary tumor (MSEMT6) showing the distribution of doxorubicin (blue,
autofluorescence) in relation to tumor blood vessels
(red, CD31 platelet/endothelial cell adhesion molecule
1 monoclonal antibody) and regions of hypoxia (green,
hypoxia-selective agent EF) in vivo. Doxorubicin is
distributed around tumor blood vessels and there is
inability to reach deep into the interstitial space where
more cells are located. From Minchinton and Tannock,
2006.

1.4 Human bone, the organ
1.4.1 Overview of the general function of bone: Bone is a dynamic system that performs
several functions. Bone provides support and locomotion to the body, and this musculoskeletal
capability is efficiently accomplished by a balance between bone mass and architecture
(Confavreux, 2011). The equilibrium between bone mass and structure allows for a lightweight
organ that is strong/flexible and tough/stiff so it is capable of sustaining mechanical strains
without fracture (Ritchie, 2010). Moreover, bone also provides protection and shelter to soft
organs, such as the lungs and marrow (Confavreux, 2011). Furthermore, bone is a storage and
exchange house for minerals such as calcium, phosphate and magnesium, which are essential for
whole-body homeostasis (Bartl and Frisch, 2009).
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1.4.2 Bone development, adaptation and morphology: The adult human body consists of
about 216 bones and every bone begins from mesenchymal condensation at embryonic
development (Bartl and Frisch, 2009). Mesenchymal condensation allows for bone formation
either by intramembranous ossification or endochondral ossification (Jee, 2001).
Intramembranous ossification produces bones such as the skull, facial bones and mandible,
whereas endochondral ossification produces bones such as the vertebra, tibia, femur and pelvis.
Intramembranous ossification is characterized by a fibrous membrane, where primary
spongiosa (the first cancellous bone) is laid down. The primary spongiosa is finally remodeled
by a vascular system. Endochondral ossification is distinguished from intramembranous
ossification by cartilaginous deposits that mature and calcify. The calcified cartilage sets the
ground for osteoblastic deposition of osteoid then to become woven bone (Majeska, 2001; Jee,
2001). The radial expansion of osteoid and woven bone creates the foundation for cortical-bone
that is replaced with primary lamellar bone and eventually by vascular canals with secondary
lamellar bone. Longitudinal expansion of this embryonic osteoid-woven bone leads to formation
of spicules that will become trabecular bone, which eventually get remodeled to trabecularlamellar bone (see Fig. 9 for illustration of trabecular and cortical bone).
Bone takes its shape and adapts by two processes, modeling and remodeling, respectively
(Fig. 6). Modeling is a developmental condition where bone surface/volume formation and
resorption drifts generate the bone’s anatomical/mechanical shape. Further into maturity, bone
remodeling takes over as a process of tissue maintenance and mechanical augmentation.
Remodeling serves to replace mechanically incompetent bone, dead bone and fractured bone and
serves to adapt bone to mechanical stimuli.
Figure 6. Diagram illustrates
the relationship between
strains (µstrain) and the
adaptive responses of a
mechanosensory system.
Minimum effective strains
(MES) are defined by
thresholds (physiological set
points) where bone mass
adjusts to strain/stress.
r=remodeling, m= modeling,
p= pathologic, Fx= fracture
From Jee, 2000.
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As stated, the groundwork-material of mechanically functional bone is the osteoid.
Osteoid is primarily formed as non-calcified collagen (mainly Type I, with traces of type II, III,
V and X), and non-collagenous protein (glycoproteins, glycosaminoglycans, RGD containing
proteins, and serum proteins) (Jee, 2001; Majeska, 2001; Robey & Boskey, 2008). Post
translational/post transcriptional modifications and manufactured quantities of these proteins are
genetically set (Majeska, 2001; Zuscik et al., 1995) and they define the tissue quality (ViguetCarrin et al., 2006) (see Fig. 7(A) for hierarchical structural organization of bone and collagen).
Successively, ionic mineral condensation, mainly calcium and phosphate, occur after osteoid
deposition. Alkaline phosphate and the non-collagenous proteins produced by osteoblasts may
regulate crystal formation (Boskey, 2001). These mineralization regulating factors, also called
nucleators, control the size, shape and composition of the crystal (Robey & Boskey, 2008) (Fig.
7 B-C).

A

C

B

Figure 7. Hierarchical structural organization of bone.
A) Cortical and cancellous and are considered
macrostructures, osteons (Haversian system) are
considered microstructures, lamellar bone (primary and
secondary) is considered a microstructure and collagen
fibers, mineral crystals and non-collagenous proteins are
considered nano structures. B) Further description of
collagen fibrils, fibers and bone mineral crystals. Shown
here is the 67 nm periodic pattern resultant from the
presence of gap (40 nm) and overlap (27 nm) regions of
the assembled collagen molecules. C) Such gap and
overlaps can be seen in a TEM micrograph of a
mineralized collagen fibril. Top images from Rho et al.,
1998, bottom image from Weiner and Wagner, 1998.
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Because of temporal and spatial differences in the tissue mineralization, human bone
contains heterogeneous bone mineral density distribution (BMDd) cross-sectionally and
longitudinally (Boskey, 2001) (Fig. 8). The BMDd provides bone with toughness against
fracture.

A

X-ray
attenuation
map

B

Trabecular strut

C

Cortical section

Figure 8. A) X-ray image of a proximal femur with its corresponding ex-vivo specimen. Delineation of
cortical and cancellous bone and marrow is shown. Lighter color bone on the x-ray is represented as
higher attenuation value (cortical and trabecular) compared to marrow, which is represented by low
attenuation values (dark color). B) Backscattered electron image of trabecular and C) cortical bone. The
surface of trabecular bone features packets of different grey-levels, which result from a heterogeneous
bone mineral density distribution. The numbers indicate the average mineral content within bone packets.
The bone packet with the lowest mineral content corresponds to fresh bone formation, whereas higher
numbers correspond to time points with more mature mineralization. Similarly we can see the
mineralization heterogeneity between the different bone structural units due to the Haversian bone
remodeling activity in cortical bone. Top images from Downey and Siegel 2006 (A); bottom images from
Fratzl et al., 2004 (B); Bala et al., 2010 (C).

Bone develops into a more mature and more mechanically efficient organ when woven
bone is replaced by a more organized structure, lamellar bone. Cortical lamellar bone is
collection of 3- to 7-µm-thick layers that run primarily parallel to the longitudinal axis of the
bone. Lamellar bone is more structured and is superior mechanically to woven bone. Lamellar
bone has well-organized collagen fiber arrangement and orientation (Viguet-Carrin et al., 2006).
Cortical lamellae can be defined as a building composite in which the principal axis is aligned
16

with that of the major input load (Rho et al., 1998). The composite nature of lamellae bone
provides bone with tougher mechanical characteristics, allowing bone to hamper fracture
expansion of micro-cracks and diffuse damage (Ritchie, 2010). Lamellar bone is also found in
trabecular bone, and it is believed that the material quality is as efficient as in cortical bone.
Lamellar bone is eventually adapted to be more competent mechanically and physiologically by
remodeling with incorporation of osteons, consider being the bone structural unit of human bone
(Bartl and Frisch, 2009). Osteons are ~200-250µm in diameter and have blood vessels,
lymphatics and nerves running through them. The replacement of primary lamellar bone by
osteons is orchestrated by the osteoclast-osteoblast coupled mechanism.

After adolescence, bone is 65-70% mineral and 30-35%
protein plus water and has a well defined nanostructure,
microstructure and macrostructure (Fig. 7). Major bone structures
are the diaphysis (bone mid-shaft), metaphysis (below growth plate
region) and epiphysis (above growth plate region), periosteum
(outer shell) and endosteum (inner shell), cortical and trabecular
bone (Fig. 9). Bone marrow and cortical and trabecular vasculature
are also fully formed by adulthood (Fig. 10).

Figure 9. Anatomical diagram of a long bone illustrating the main bone
regions such as the epiphysis, metaphysis, diaphysis, and cortical and
trabecular bone. Open and fused growth plates are also shown, along
with the periosteal and endosteal surfaces. From Downey and Siegel,
2006.
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A

Figure 10. A) a schematic diagram
of the vascular arrangement in the
diaphysial region of a long bone;
Depiction of the nutrient artery,
nutrient vein, proximal and distal
bifurcation are seen. B) The
arterial tree in the bone marrow
space will eventually turn into
sinusoids and the capillary bed in
the cortical section of the bone. The
radial branches of the nutrient
artery form a leash of arterioles
that penetrate the endosteal surface
to form the Haversian system. From
Cowin, 2010.

B
1.5 Bone cells

1.5.1 Bone cells and their lineage: Bone cells come from pluripotent stem cells located in
the bone marrow. Mononuclear phagocytic hematopoietic stem cells give rise to osteoclasts,
while osteoblasts are derived from mesynchymal stem cells (Krause et al., 2009; Ross, 2008)
(Fig. 11). Osteocytes and lining cells are a further stage of differentiation from mature osteoblast.
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Osteocytes get buried into the bone matrix and lining cells are quiescent and disperse in the bone
surfaces (Bartl and Frisch, 2009).

Figure 11. Bone cell lineage. The osteoclasts are derived from cells in the mononuclear phagocyte
lineage. Osteoblasts are derived from the hematopoietic stem lineage. Osteoblasts sub-divide into
categories: 1) the osteoblasts themselves, 2) bone lining cells, and 3) osteocytes. Bone lining cells are
basically inactive osteoblasts (not shown) that cover bone surfaces. Osteocytes are osteoblasts that have
become encased in bone matrix during bone tissue production. From Ralston, 2009.

1.5.2 Osteoclasts are known as the demolition cells of bone (Fig. 12). These cells have an
approximate diameter of ~100µm in the fully multiple-nucleated form. Fully differentiated
osteoclasts attach to bone surfaces and perform resorptive activity. (Bartl and Frisch, 2009).
Osteoclasts secrete protons, ions and matrix metalloproteinase (MMPs) to demineralize the tissue
and degrade protein. Major regulating
factors of osteoclast activity are PTH,
prostaglandin and vitamin D, which are
osteoblast-osteoclast OPG-Rank
signaling stimulators (Zuscik et al.,
1995; Ross, 2008). Inhibitors of
osteoclasts activity include calcitonin,
Figure 12. Multinucleated osteoclasts resorbing bone to
form resorption pits known as Howship’s lacunae. From
Clarke, 2008.

calcium, and bisphosphonates.
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1.5.3 Osteoblasts are bone forming cells

(Fig. 13) because they produce the groundworkmaterial of mechanically functional bone, the
osteoid. Osteoblasts are ~15-30µm in diameter
and work on preexisting surfaces that have been
previously created either by chondrocytes (in
formation of bone in developmental phase), or
by osteoclasts (formation of bone in remodeling)
(Bartl and Frisch, 2009). It is known that after
Figure 13. Osteoblasts synthesizing
proteinaceous matrix, composed mostly of
type I collagen, to fill in resorption pits. The
proteinaceous matrix is gradually
mineralized to form new bone. From Clarke,
2008.

osteoblasts finish bone formation, they undergo
apoptosis, or they become osteocytes or bone
lining cells. Osteocytes, osteoblast and bone
lining cells are connected through gap junctions
and communicate to regulate bone function

(Clarke, 2008). Major activating factors of osteoblasts are morphogenic proteins (BMPs) and
stimulating growth factors (IGFs, TGFs and FGFs) (Zuscik et al., 1995; Krause et al., 2009).
1.5.4 Osteocytes are matrix-embedded osteoblasts

(Franz-Odendaal et al., 2006) (Fig. 14). Osteocytes are a
network of cells interconnected by gap junctions. It is
believed that osteocytes control the efflux of mineral in
an orchestrated manner with help of osteoclasts and
bone lining cells (Bonewald and Johnson, 2008).
Osteocytes also detect and might repair microcracks.
Given to their advantageous distribution within bone,
Figure 14. Bone slice injected in vivo
with reactive red (∼1-nm diameter).
Staining shows vascular pore, osteocyte
lacunae, and canaliculi. From Fritton
and Weinbaum,2009.

osteocytes are believe to be the mechanical transducers
of bone (Franz-Odendaal et al., 2006) (Fig. 15), and they
are believed to control bone formation by regulation of
inhibiting factors such as sclerostin (Robling et al.,
2008).
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Figure 15. Mechanical
loading hierarchy starting
at the whole bone organ
and then transmitted
through the bone tissue
down to the cellular level.
The mechanical forces
stimulate osteocytes,
which react by inhibition
or enhancement of tissue
turnover. From Fritton
and Weinbaum, 2009.

1.6 Bone remodeling
Osteoclasts and osteoblasts play a major role in bone formation and adaptation. The bone
building unit (Fig. 16) also known as osteoclast-osteoblast cell coupled mechanism, completes
the formation of osteons (Bartl and Frisch, 2009) and maintains bone quality.

Figure 16. Bone
remodeling building unit.
Depiction of the
resorption and forming
cone phases are present.
Osteoclasts and
osteoblasts are the main
players. Blood vessels,
which bring the nutrients
and precursors of bone
cells, are formed
simultaneously. At the end
of the resorption and
forming cone, there is
lamellar bone formation,
a Haversian vascular unit
and osteocytes present.
From Cowin, 2001.
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1.7 Bone porosity, permeability, and interstitial fluid flow
Bone is a porous saturated solid material. The porous-elastic behavior of bone provides
the means for interstitial fluid flow caused by mechanical tissue strains. The mechanical loading
deformations define the convective transport behavior of large molecules within bone. When
mechanical loads are applied to bone, for example during walking, fluid pressure gradients are
produced in the connected bone pores, creating interstitial fluid displacement. This load-induced
fluid flow enhances mass transport in healthy bone and ensures the metabolic function of bone
cells that is crucial for bone maintenance (Fritton and Weinbaum, 2009). Interstitial fluid
pathways in bone have been quantified using vascular injection of molecular tracers (KnotheTate et al., 1998; Wang et al., 2004; Ciani et al., 2005). Investigators have also used tracer
methods to experimentally confirm the existence of load-induced transport within bone
tissue; applying mechanical loading to animal limbs has demonstrated an enhanced delivery of
tracer molecules through the bone tissue (Knothe-Tate et al., 2000; Tami et al., 2003). The
interstitial fluid flow is related to the bone permeability and therefore to the bone porosity.
Porosity in bone can be defined as follows 1) the space occupied by the lacunarcanalicular network, 2) the space occupied by the vascular system, 3) the collagen-apatite
porosity, and 4) the space between the trabecular plates and struts. The collagen-apatite porosity
is not connected and is extremely small (~10nm); the water is considered bound to the surfaces,
therefore having no effect on the interstitial fluid flow (Gailani et al., 2009). The trabecular bone
porosity contains the greatest porosity range and it is profoundly defined by the porosity
orientation and anatomical location. Fluid flow in trabecular bone occurs when marrow moves
around the plates and struts. Lacunar-canalicular fluid flow occurs when interstitial fluid (mainly
water and ions) moves between the osteocyte body and the lacuna wall and between the cell
process and the canaliculi wall. This flow in the lacunar-canalicular system is an important
predictor of cellular communication and mass transport (Knothe Tate et al., 2004).
Several studies on the values of porosity and permeability report vascular porosity
ranging from 0.04 to 0.06, vascular permeability ranging from ~5.0x10-15 to ~7x10-8 m2; lacunarcanalicular porosity ranging from ~0.023 to ~0.05, lacunar-canalicular permeability ranging from
~1.0x10-20-~1.0x10-24 m2; a trabecular porosity ranging from 0.1 to 0.95, and a trabecular
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permeability ranging from ~1.0x10-8 to ~1.0x10-3 m2 (Cowin, 1999; Cowin, 2010; Gardinier et
al., 2010; Beno et al., 2006).

Figure 17. Sketch showing cross
section of an osteon. Four
features are depicted: 1) the
osteonal canal porosity including
a blood vessel, 2) the lacunae
and the canalicular porosity, 3)
the material in the space between
the lacunar–canalicular porosity
contains the collagen–apatite
porosity, and 4) cement line.
From Cowin, 2001. Trabecular
porosity can be seen in Figs. 8
and 9.

1.8 Overview of bone cancer
1.8.1 Primary bone cancer: Primary tumors arise from the tissue/organ where they are
located and can be classified either as benign or malignant (cancer). Primary tumors start as
benign and might transform into malignant cancers. Primary malignant tumors arising in the
skeletal system are rare, representing just 0.001% of all new cancers (Malawer et al., 2005).
According to the Surveillance Epidemiology and End Results (SEER) cancer statistics review
(CSR) from the National Institutes of Health (NIH), in the United States 1.0 per 100,000 men
and 0.8 per 100,000 women will be diagnosed with some type of bone or joint-related cancer.
Furthermore, 0.5 per 100,000 men and 0.4 per 100,000 women will die of this disease.
The main types of primary cancers to bone include osteosarcoma (predominately produce
osteoid) (Fig. 18) and Ewing's sarcoma (Malawer et al., 2005). These primary bone cancers are
rare, and are considered the cancer of the young; patients are usually between ages 10 and 25.
There exist cartilage-forming tumors in bone, such as osteochondroma, enchondroma, and
chondrosarcoma, which can be intramedullary or peripheral. Also, osteoid forming tumors are
lesions where the stroma produces osteoid, such as osteoma and osteoblastoma (Malawer et al.,
2005).
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A

B

Figure 18. A) Inverse magnetic resonance
imaging demonstrating the intramedullary
extension of osteosarcoma in human proximal
tibia. B) X-ray radiograph marks sclerosis of
osteosarcoma of the distal femur. Damage can
be seen within the intramedullary canal and a
posterior extraosseous component that shows
osteoid formation. From Malawer et al., 2005.

1.8.2 Secondary bone cancer; metastasis to bone: Secondary tumors are malignant
cancer cells that originally developed in a distant organ/tissue from where they detached. These
tumors develop genotypic and phenotypic characteristics that are similar to the tissue from where
they came from and acquire traits from the environment where they metastasized. Metastases can
happen at any age; however, metastases to bone are more frequent than primary bone tumors and
usually affect older people (Manoso and Healey, 2005). Cancers that preferentially metastasize
to bone are breast, kidney, lung, prostate and thyroid (Manoso and Healey, 2005).

1.8.3 Staging and classification of bone tumors: Classification of bone tumors can be
given by the rate of cell growth, subsequent progression, degree of invasion and whether
metastasis has occurred (Malawer et al., 2005; Lichtenstein, 1951). Tumor presence in bone can
also be classified by anatomic location and border pattern. Benign lesions present well-defined
borders in contrast to transitional borders, which are more aggressive, faster-growing tumors
indicative of malignancy. Bone destruction is a strong predictor of tumor aggressiveness, in
contrast to matrix formation, where malignancy cannot be predicted by its presence
(Lichtenstein, 1951). Finally, a bone tumor can be staged by its histological involvement and
lymph node involvement.
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1.8.4 Effects of tumor growth in bone: Bone tumor growth in itself is associated with
compromised hematopoiesis, lack of erythrocyte and platelet creation, compromised leukocyte
production, metabolic disorders such as hypercalcemia, which can occur in patients with
extensive metastatic disease, spinal cord compression (Koutsilieris, 1995) and pain and
immobilization. The last two symptoms largely contribute to the diminishment of a patient’s life
quality. The destruction of the bone architecture is caused predominantly by stimulated bone
cells and this process is independent of the tumor growth. Involvement of cancer cells in bone
destruction is indicative of higher degree of malignancy (Manoso and Healey, 2005). Bone
tumors provoke three general types of lesions: sclerotic, lytic and mixed (see Fig. 18 for details)
(Vassiliou et al., 2007). These lesions are characterized by osteoblast-dependent and/or
osteoclast-dependent mechanisms stimulated by over-expression of growth factors.

1.8.5 Evaluation, side effects and treatments against bone cancer; emphasis on
bisphosphonates, the drug and tracer: Radiographic evaluation, combined with the clinical
history and histological examination, is necessary for accurate diagnosis of bone cancer. Bone
scans, angiography, CT, and MRI are generally not helpful in determining a diagnosis but are
important in delineating the extent of local involvement (Malawer et al., 2005).
Primary and metastatic bone tumors are treated using chemotherapy, and adequate drug
delivery is required for significant therapeutic effect. In some cases chemotherapy is used to
reduce the size of the tumor before surgery; otherwise it is used to treat the underlying disease.
Some chemotherapeutic drugs used to treat sarcoma include doxorubicin, ifosfamide, etoposide,
cisplatin and methotrexate (Ta et al., 2009). Cancer patients going through chemotherapy also
receive an antiemetic regimen to decreased side effects such as vomiting, incontinence, fever and
skin sensitivity. However, more serious side effects include anemia, transient elevation in
bilirubin, peripheral neuropathy, hearing loss, electrolyte disturbances such as hypomagnesemia,
hypocalcemia, and hypokalemia, heart failure, somnolence, hallucinations and others (Berger
and Clark-Snow, 2005; Weiss, 2005). Chemotherapy is administrated intravenously or orally.
Treatment can take several hours, while prescribed regimes might be spread within a few days,
weeks or months (Spira and Ettinger, 2002). Adjunct treatments to chemotherapy can include
hormonal therapy, anti-angiogenic drugs, genetic therapy and others.
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Surgery and radiotherapy are also common treatments in bone cancer. Metastatic bone
cancer may require the addition of hormonal therapy, immunotherapy, and bisphosphonate
therapy (Manoso and Healey, 2005).
Bisphosphonates are analogues of pyrophosphate (Phosphorous-Oxygen-Phosphorous (PO-P)), and they have important anti-resorptive properties in bone (Roelofs et al., 2006).
Bisphosphonates are used to treat metabolic diseases such as cancer-induced bone osteolysis,
osteoporosis and hypercalcemia. Bisphosphonate long-term action in the body is based on the
principle of lack of enzymatic degradation (Malawer et al., 2005). Non-enzymatic degradation
provides bisphosphonates with long half-lives (decades). Different bisphosphonates exist, but the
most efficient/stronger acting ones are those that contain nitrogen in their chemical structure
(Russell, 2007). The phosphate groups within bisphosphonates allow them to attach to
hydroxyapatite crystal (Russell, 2007), creating efficient bone uptake and retention. At the
cellular level, bisphosphonates interfere with the mevalonate pathway by inhibiting farnesyl
pyrophosphate within cells, leading to cell death (Roelofs et al., 2006). Not only are osteoclasts
affected by bisphosphonates, but also osteocytes become hyperactive and lymphocytes
proliferate in vivo (Bukowske et al., 2005). Such effects might explain the effects of
bisphosphonates in tumor burden.
The bisphosphonate pamidronate has been shown in several studies to be effective in
treating osteolytic disease (Manoso and Healey, 2005). Pamidronate is an intravenous-delivered
bisphosphonate (Gatti and Adami, 1999) used not only to prevent progression of the bone
destruction but also to palliate pain. Pamidronate retention in patients with breast cancer
metastasized to bone (infused monthly) is highly variable but the uptake is large, and its antiresorptive effects are dependent on previous treatments (Cremers et al., 2005).

1.9 Animal models of bone cancer
1.9.1 Bone metastases models: To allow for a better understanding of the biological
complexity that characterizes metastases, in vivo animal models are required, given that in vitro
models cannot always provide enough data (Khanna and Hunter, 2005) such as a inclusion of a
vascular system and high interstitial pressure. In cancer research, in vivo models of bone
metastasis with human cells consist of injections/inoculation of cancer cells orthotopically, intracardially/arterially, intravenously (via the tail vein), directly intra-osseous (intrafemoral and
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intratibial) and xenograft transplantation into immuno-compromised hosts (Degraff et al., 2009;
Blouin et al., 2005) like mice or rats. Even though the early steps of metastases cascade is
overlooked/eliminated in some animal models (escape of primary tumor, embolism, invasion of
new tissue and extravasation (Khanna and Hunter, 2005)) such as transplantation and injection,
the histo-pathological phenotype is reproduced, and the bone-cancer cell interaction can be
quantified (Degraff et al., 2009). It is important to keep in mind the effect of the lesion caused by
the injection and inoculation of cells; it is important to validate and interpret the physiological
response (Blouin et al., 2005). There exist spontaneous murine models of cancer such as lung,
breast, prostate, and kidney, but the probability of metastases to bone is rare or null (Degraff et
al., 2009; Blouin et al., 2005). Genetic changes to the animals increase the probability of
spontaneous cancer that metastasizes to bone; however, genetically modified mice or rats might
not represent the human body as well as a syngeneic cancer model (Degraff et al., 2009). For
example, nude mice that have T cell depletion have impaired angiogenesis (Khanna and Hunter,
2005). Syngeneic cancer models allow for the use of immuno-competent animals with cancerous
cell lines of the same species; therefore a better representation of cancer-host interaction can be
achieved (Khanna and Hunter, 2005).

1.9.2 Walker 256 cancer cells; from breast to bone: The selectivity of cancer cells to
metastasize to bone is due to the rich growth factor environment that acts as a chemo-attractant
and because of expression of selective adhesion molecule (Blouin et al., 2005). In breast cancer,
Walker 256 (W256) cancer cells were discovered in the mammary gland of a 10-month-old
albino rat (Blouin et al., 2005). W256 are considered carcinoma and sarcoma because of the
presence of several cell types in the tumor mass. W256 do not express estrogen receptors (Blouin
et al., 2005), but produce parathyroid hormone-related protein PTHrP. Intra-arterial injection of
W256 cancer cells that metastasize to bone provoke bone destruction as fast as in 7 days in rats
(Degraff et al., 2009). Intratibial injection of W256 cancer cells in rats provoke bone
deterioration detectable by day 20, which included medullary bone loss and full thickness
unicortical and/or bicortical bone loss. (Mao-Ying et al., 2006). Morphologically, W256 are
large, contain an oval shaped nucleus, have a high nucleus to cytoplasm ratio, contain smooth
membranes but with microvilli and have a dense rough endoplasmic reticulum. Immunohistochemistry analysis indicates that W256 are derived from primitive hematopoetic stem cells
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(Simpkins et al., 1991). W256 produce matrix metalloproteinases such as MMP9 (Pavlaki et al.,
2009 and they have been proof sensitive to cisplatin and chlorambucil in vitro (Simpkins et al.,
1991).

1.10 Imaging technology in bone cancer
1.10.1 Radiography and computed tomography (CT): In the clinic CT and radiography
utilize the principle of x-ray beam attenuation of the electromagnetic wave passing through a
specimen (Kalogeropoulou et al., 2009) to image for tissue abnormalities. The degree of
attenuation is mainly determined by the density and thickness of the specimen. Dense materials,
such as the calcium crystal in bone, attenuate the x-ray beam, whereas, marrow and blood have
less attenuation. A thick tissue attenuates an x-ray beam more than a thinner tissue of the same
type. Accordingly, the tumor effects in the bone architecture can be delineated by x-ray.
Radiography is commonly used in the clinic. It is inexpensive and fast; however, CT is rapidly
becoming the first examination because of its 3D capabilities (Malawer et al., 2005). In research,
CT has been used to quantify structural damage (changes in bone volume fraction) and its
relation to bone fracture (trabecular and cortical thickness and shape) (Nazarian et al., 2008;
Hildebrand et al., 1999). In the clinic, simple correlations have been used to identify fracture risk
in patients with bone cancer as well as osteoporosis (low bone mass implies higher risk of
fracture). Animal models of bone cancer and high resolution microCT have been used to
correlate bone destruction levels to 2D densitometry measurements, and the risk of fracture
(Kurth et al., 2001). Standard density measurements such as simple radiographs do not predict
fracture as described my micro-CT.
Bone radiographs in cancer remain a vital element in characterizing many bone lesions
by demonstrating abnormal physical characteristics such as calcified cartilaginous or osseous
matrix within a bone (Manoso and Healey, 2005). The x-ray morphogenic patterns seen in bone
cancer: osteolytic, osteoblastic, and mixed are the characteristics in radiography
(Kalogeropoulou et al., 2009). In cancer, a trend between x-ray lesion type and origin of
metastasis to bone has been seen such that in prostate carcinoma lesions tend to be of blastic
appearance, whereas breast carcinomas are predominantly mixed or lytic. Lung, thyroid, and
renal carcinoma usually appear purely lytic (Manoso and Healey, 2005).
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CT has become useful for the three-dimensional evaluation of bone integrity and because
of its improved spatial resolutions and easier discrimination of the soft tissue component. Also,
CT can provide a basis for computer aided design (CAD) models for mechanical-competence
analysis such as finite element (FE) modeling (Kalogeropoulou et al., 2009). However, CT has
its limitations, such as it delivers substantial doses of ionizing radiation to the tissue compared to
plain radiography.

1.10.2 Single photon emission computed tomography (SPECT) and positron emission
tomography (PET): Nuclear medicine (NM) is an example of a functional imaging modality,
where abnormal biological and physiology activities can be discriminated from normal activities
(Hicks, 2005). The two main imaging modalities used in NM are SPECT (Beekman and Van der
Have, 2007) and PET (Zanzonico, 2004). In SPECT, the radioactive detector is sensitive to
individual gamma rays, and focusing is done with a lead collimator; however, its spatial
discrimination is relatively poor (Beekman and Van der Have, 2007). PET works in a similar
manner to SPECT; it uses a ring of scintillation detectors sensitive to photons that are attached to
photomultipliers that allow for co-registration of paired annihilation events (Zanzonico, 2004).
NM imaging involves administration of a radioactive tracer and non-invasive detection of its
distribution within the body (Malawer et al., 2005; Manoso and Healey, 2005). The distribution
of the drug may be related to the pharmacodynamics, and is generally also affected by “nonspecific” factors as blood flow/perfusion, vascular permeability, rates of excretion and
metabolism, binding and others. Tracers used in SPECT are 99mTc-MDP, thalium 201, 99mTcMIBI, 99mTc-DMSA and tracers used in PET are 18F-fluoride, 18F-FDG and 18F-fluorothymidine
(Hicks, 2005). In bone, SPECT technetium scans rely on the incorporation of tagged
bisphosphonates. Bisphosphonates bind to exposed hydroxyapatite crystals. Nevertheless, bone
scans are not specific, nor do they provide structural detail of the bone. Plain radiography, CT or
MRI are required in NM to evaluate benign and malignant lesions and improve spatial resolution
(Malawer et al., 2005).
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Chapter 2 Preliminary Study to Assess Enhancement of Drug Uptake
Due to Mechanical Loading
2.1 Introduction, hypothesis and aim
Primary and metastatic bone tumors are treated using chemotherapy, hormonal therapy,
immunotherapy, and bisphosphonate therapy, and adequate drug delivery is required for
significant therapeutic effect. To obtain more effective drug delivery, this project investigated the
efficacy of applying non-invasive physiological mechanical loading to enhance uptake of
bisphosphonates to bone tumors. The investigation used a rat Walker 256 (W256) tibial tumor
model and 99mTc-labeled pamidronate as the tracer quantified using gamma camera scans. We
considered the following hypothesis and aim:
Hypothesis: Non-invasive physiological mechanical loading increases drug delivery to
bone tumors.
Aim: To quantify 99mTc-labeled pamidronate uptake into rat bone tumors after noninvasive mechanical load application using a previously developed non-invasive tibia loading
device that provides a precise, controlled loading magnitude and rate.
2.2 Methods
2.2.1 Summary of approach: W256 rat mammary carcinoma cancer cells were cultured in
sterile conditions prior to cell inoculation. The W256 cancer cells were injected into the rat tibia
as a model of bone metastasis, which produces predominately osteolytic bone tumors. Tumor
confirmation was completed 21 days after surgery with in vivo microCT. Tail vein injection of
99m

Tc-labeled pamidronate was performed, followed by mechanical loading of tumor-bearing

tibia using a non-invasive loading system that provides a precise, controlled loading magnitude
and frequency (load input, displacement-controlled system). The delivery of 99mTc-labeled
pamidronate to bone tumors was assessed using gamma camera scans (Table 1). Controls were
the contralateral non-tumor bearing tibiae that did not undergo mechanical loading.
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Chronological outline of experiments
Time Line
Action
Day = 0
Walker 256 cell culturing process (~2 week process)
Day = 15
Intra-tibial injections of cancer cells (1 day process)
Day = 36-42
MicroCT scans (confirmation of tumor-related lesions)
Day = 47-56 1. Tail-injections of 99mTc-labeled pamidronate
2. Non-invasive mechanical loading
3. Gamma camera scans
4. Animal sacrifice and tissue harvesting
Onward
Imaging analysis
Table 1. Time line of experiments.

2.2.2 Cell culturing: W256 cells were obtained from ATCC (CCL-38™, LLC-WRC 256)
with a cell concentration of 1.0M W256 cells per ml. Cells were plated on a t75 flask (75 cm2)
and incubated at 95% humidity, 5% CO2 and 37 Cº. Fresh media (M-199 powder, Sigma
Aldrich) was prepared according to ATCC recommendations. 94% media, 5% horse serum and
1% antibiotic (Penicillin-Streptomycin Solution, Sigma Aldrich) was used with a 7.3 pH level.
Media contained Earle′s balanced salts and L-glutamine; sodium bicarbonate was added after
dilution with sterile water. Cells were fed every two to three days. To obtain an adequate number
of cells, cells were passaged only two times to prevent cellular modification. Passages were
performed using the trypsinizing standard method followed by centrifugation, cell counting and
re-plating.
2.2.3 Establishment of bone tumors by injection of cancer cells: All animal protocols
were approved by the Institutional Animal Care and Use Committee at Memorial SloanKettering Cancer Center. 11-week-old female Sprague Dawley rats (n=12, 250g ± 27g) were
obtained from Charles River (Wilmington, MA) and allowed to acclimate for one week, so that
rats were 12 weeks old at the time of intratibial injections. To insert cancer cells into the tibia,
the rats were anaesthetized using 3%-4% isoflurane plus 20% oxygen administered using a
precision vaporizer induction chamber. Using a nose cone, anesthesia was maintained using 1%1.5% isoflurane plus 20% oxygen. The right knee was shaved and cleaned with povidone-iodine
solution and 70% ethanol pads. The tibia was exposed with an incision (approximately 5 mm)
made along the patellar ligament, and a 28G needle was used to inject 2.5M W256 cells/ 25µL.
The 28G needle was inserted through the periosteum into the metaphysis about 7 mm below the
knee joint into the medullary canal. Initially, the needle was used to remove some of the bone
marrow to create volume for the cells, and then the cells were injected in saline solution. The
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needle was kept in place for ~2 minutes to prevent suspension egress, and a 10 µl volume of
saline was used to push any leftover cell suspension from the needle cannula. The needle was
removed and the injection site was closed using bone wax. The small skin incision was closed
with surgical glue. Subcutaneous 0.05mg/kg of Buprenorphine (Buprenex 0.3mg/ml) was
administrated after surgery. Extra dosages were applied if needed.
2.2.4 In vivo microCT 21 days post-surgery to assess tumor growth: Each rat was
anesthetized using isoflurane plus oxygen in an induction chamber. The rat was moved to the
SPECT-μCT (X-SPECT Gamma Medica, Northridge, CA) and placed in a custom-made holder.
A nose cone continued the administration of isoflurane plus oxygen for the duration of the scan
at a lower concentration. A 45-minute microCT scan of 256 frames (projections) was taken.
Preset values for voltage (100Kvolts) and current (100µamps) were used. System calibration
(measurement of the position-dependent x-ray flux incident on the detector on air) and
measurement of system background (measurement of the apparent x-ray flux with the x-ray tube
off) were performed by acquisition of “bright” and “dark” fields, respectively, immediately prior
to imaging of each animal. After scanning, the rat was monitored until it regained consciousness.
2.2.5 Radiotracer injection 29 days post-surgery: Rats were weighed and then
anaesthetized as previously described. While keeping the animal warm with the use of a heat
lamp, a tail injection of 99mTc-labeled pamidronate at a dosage of 1mg/kg with an activity of
approximately 250 MBq (7-9 mCi) dissolved in 0.8 ml of saline was administrated.
2.2.6 Mechanical loading; drug delivery enhancement: As quickly as possible after
injection, and keeping the rat anesthetized with ~2% isoflurane and 20% oxygen, the rat leg was
positioned in the loading machine with a preload ~1N to hold the leg in position (Fig. 19). 10
minutes of cyclic indirect, displacement-controlled non-invasive mechanical loading was applied
to the rat tibia along its longitudinal axis with ~800 microstrain of deformation at a frequency of
1Hz for a total of 600 loading cycles, a loading that imitates walking.
Figure 19. Non-invasive loading device (TestBench
ElectroForce, Bose Corp.). The rat tibia is constrained
by foot and knee holders (blue arrows), while the
actuator applies a sinusoidal compressive load (red
arrows) (cyclic compressive loading of -2N to -18N).
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2.2.7 Gamma camera scanning; uptake measurements: Immediately after loading and
keeping the rat anesthetized, the rat was positioned in the microSPECT system in the custommade holder. The gamma camera was placed as close as possible to the animal to enhance the
spatial resolution. However, for proper comparison between samples, the gamma camera was
placed at the same distance for all animals (Fig. 20, X2< X1, H2 gamma camera was used, X2
equal for all animals). Planar gamma camera scans were taken for 45 minutes. Three sets of
scans were taken for a total of 60 frames: 30 frames @ 10 sec each, 25 frames @ 60 sec each and
finally 5 frames @ 180 sec each. After the imaging was finished, the rats were sacrificed by
carbon dioxide inhalation.
Direction of movement
SPECT
system

Laser alignment system
Figure 20. Rats were placed in the microSPECT system on a custom-made holder (black arrow) and 2D
planar dynamic images were obtained from the gamma camera. In vivo gamma camera images were
taken to assess pamidronate uptake after mechanical loading. Planar dynamic acquisition consisted of 3
sets of scans - 30 frames @ 10 sec each, 25 frames @ 60 sec each and 5 frames @ 180 sec each –
or a total of 60 frames over 45 min.

2.2.8 Tissue harvesting: After sacrifice, the tibia and fibula were removed, keeping the
surrounding tissue, including the skin. The harvest procedure was performed in an extremely
delicate manner because excessive tissue handling can modify the activity distribution. All tissue
was labeled properly for further studies. Excised tissue (tibiae, muscle, and skin) was placed in
laboratory tubes, labeled and stored in a refrigerator for 24 to 36 hours.

2.2.9 Data analysis: Gamma camera scans were analyzed by choosing anatomical regions of
interest (ROI) as follows: 1) whole tibia ROI, 2) tibia head ROI with tumor area included and 3)
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background ROI for calibration procedures (Fig. 21). Gamma camera data sets were properly
corrected for radioactive decay and to the injected dose activity. Background count density
(count per pixel) was subtracted from the count density in each ROI and the resulting count-rate
data were expressed “per-gram” of tissue. Overall, gamma camera analysis consisted of mean
cpm (counts per minute per pixel). Data from the closest gamma camera receiver (H2, see Fig.
20) was analyzed because of its higher spatial definition. Equation 1 was used to find the mean
activity increase between groups. Statistical analysis was performed using a student’s t-test to
compare loaded tumor bearing tibiae activity levels to unloaded non-tumor-bearing tibiae
activity levels (p<0.05).

Eq. 1

B

A

Background ROI

C

Background
ROI

Figure 21. 2D gamma camera images. Three regions of interest (ROI) were analyzed for each rat: the
tumor site (A), the whole tibia (B) and the background (A and B). (C) An example of a 3D SPECT
tomographic reconstruction fused with microCT images demonstrating radiolabeled pamidronate
localization within the tibia. Because of time intensiveness and difficulty with co-registering the 3DmicroSPECT images were not feasible for a large quantitative analysis.

2.3 Results
2.3.1 Success rate of tumor formation: All animals survived the surgical procedure.
Normal activity, locomotion and food and water consumption were seen in all rats. Few animals
received subcutaneous buprenorphine administration to control pain a few days after surgery.
Complete 3D analyses of the in vivo microCT scans obtained 21 days post-surgery
demonstrated a 33% success rate for tumor induction. Analysis of x-ray reconstructions
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demonstrated that the tibiae suffered from mixed lesions (see Fig. 22 for an example of sclerotic
lesion). Bone deposits and smaller lytic endosteal lesions were seen within the bones that
developed tumors. Pain control from tumor growth and bone destruction was not necessary; no
tumors were allowed to develop into the cortical bone region.

Figure 22. Rat
microCT images
from day 21 post
cancer cell
injection. 3D
maximum intensity
projection (MIP)
image (left panel)
2D MIP images (two
right panels) of right
proximal tibia (red
circle) showing
sclerotic lesion
(yellow arrows).

2.3.2 Difference in drug delivery due to mechanical loading: Gamma camera data
analysis performed 29 days post surgery showed that non-invasive mechanical loading of the
tumor bearing rat tibiae increased 99mTc-labeled pamidronate delivery by 34.0% ± 7.5% in the
tumor ROI and 28.9% ± 18.8% in the whole tibia ROI, when compared to unloaded non-tumorbearing contralateral tibiae (p<0.05) (Fig 23 and 24).
Whole tibia ROI

Tumor ROI

A

B

Figure 23. Average time activity curves for the loaded and control regions of interest for all rats as measured
by gamma camera (mean ± SD). A) Tumor ROI and B) Whole tibia ROI. cpm = counts per minute;
measurements are scaled to the administered 99mTc activity (in mCi).
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Tumor ROI

A

Whole tibia ROI

B

Figure 24. Mean count activity for all time points for loaded versus control (n=12). A) Tumor ROI and
B) Whole tibia ROI. cpm = counts per minute; measurements are scaled to the administered 99mTc
activity (in mCi). Student t-test was implemented with a *p < 0.05.

2.4 Discussion, conclusions and limitations
The increased uptake of 99mTc-labeled pamidronate reflects the increased pressure
differences caused by the mechanical loading. The results demonstrate that mechanical loading
can enhance drug delivery to tumors that would likely be clinically efficacious. While the results
from this preliminary study are promising, the study has several limitations that will be
overcome using improvements developed and described in Chapter 3. Future experimental
improvements to the methods include 1) increased cancer cell viability after injection, 2)
enhancement of cancer cell inoculation by arthrotomy surgery instead of direct tibial injection, 3)
shifting from 2D planar SPECT to 3D microPET imaging, 4) use of tumor-bearing tibiae as
controls, 5) use of the clinically relevant Herceptin as the injected drug, and 6) implementation
of high-resolution microCT and histology to assess bone destruction from tumor growth.
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Chapter 3 Development of Improvements in Project Methods
3.1 Overview of planned changes
The limitations seen in the pilot study directed us to evaluate and improve several aspects
of the methodology of our approach including 1) optimizing cancer cell viability after injection,
2) improving cancer cell inoculation surgery to enhance success of tumor formation, 3) shifting
from 2D (planar) gamma camera imaging to 3D (tomographic) microPET to imaging to improve
spatial resolution, 4) using tumor-bearing tibiae as controls, 5) using the clinically relevant
Herceptin as the injected drug, and 6) implementation of high-resolution microCT and histology
to assess bone destruction from tumor growth. These improvements, which will be used in
upcoming planned experiments, are described in more detail below.

3.2 Optimization of cancer cell viability
3.2.1 Cell viability study: Because injection through a needle creates shear stresses on the
cell membrane that could cause cell membrane rupture and death, a study was performed to
investigate the viability of Walker 256 (W256) cells after injection through a syringe. To mimic
the previously performed experiments (injected cell density of 2.5M Walker 256 cells in 25µL of
saline), the cell viability test consisted of utilizing W256 cells at two concentrations: 2.5 million
cells per 25µL and 1.25 million cells per 25µL and two types of needle gauges: 28G and 22G.
For control groups a standard micropipette was used for the injection.
Two frozen vials with a cell concentration of 5M W256 cells/mL were plated on t75
flasks. After cell passage, six flasks were obtained that contained ~15M cells each, adding a total
of ~100M cells. W256 cells were trypsinized, centrifuged and counted. The cell pellet was
diluted into 1000µL of fresh media. From the 100M cells / 1000 µL solution, specific volumes
were extracted with proper cell concentrations to be utilized for the viability test (Table 2).

Concentration 1 (2.5M cells/ 25µL) & Concentration 2 (1.25M cells/ 25µL)
22 Gauge Syringe
28 Gauge Syringe
Control (Regular Pipette)
Volume = 25µL
Day 0
Volume = 25µL
Day 0
Volume = 25µL
Day 0
Volume = 25µL
Day 1
Volume = 25µL
Day 1
Volume = 25µL
Day 1
Volume = 25µL
Day 2
Volume = 25µL
Day 2
Volume = 25µL
Day 2
Volume
=
25µL
Day
3
Volume
=
25µL
Day
3
Volume = 25µL
Day 3
Total
100 µL
100 µL
100 µL
Table 2. Experimental setup for viability test. Cell concentrations and needles used, specific volumes and
days of measurements are shown.
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3.2.2 Injection procedure and cell death quantification: By removing the syringe plunger
the cell suspension was introduced using a 2000µl micropipette. The 25µL cell suspensions were
continuously injected (through the appropriate needle) at equal velocity and pressure into
centrifuge tubes containing a specific volume of media. Cell number and viability were measured
by cytometry. Analysis by light microscopy allowed for quantification of cell viability by the use
of Trypan blue (volumetric ratio of 1:1), which stains dead cells. Cell viability quantification was
completed on the same day of the test (Day 0= 0h), and after three successive days (Day 1=24h,
Day 2= 48h and Day 3= 72h) in culture. 100mm dishes (surface area of 55cm2 and final holding
cell concentration of 14M cells) were used for cell growth analysis.

3.2.3 Results of cell viability study: Cell death created by injection shear stress was zero
except for the 28G syringe with the 2.5M cells/ 25µL concentration, where a ~4% cell death was
observed. There was a decrease in cell number after injection through the 28G and 22G syringes
compared to control values except for the 22G syringe with 1.25M cells/ 25µL concentration
(Fig. 25). In terms of cell growth (Day 1-3), cells injected with the 28G syringe grew to a higher

Cell concentration after
injection
# of cells after injection
(in Millions)

3.5
3

2.5
2

Control
28G
22G

1.5
1
0.5
0
2.5M cells/ 25µL 1.25M cells/ 25µL

Cell Suspension Concentrations

Decrease % of Walker 256 cells after injection

concentrations compared to cells injected with the 22G syringe and controls (Figs. 26 and 27).

% Decrease of Walker 256
cells after injection
35
30
25

Control
28G
22G

20
15

10
5
0
2.5M cells/ 25µL 1.25M cells/ 25µL

Cell Suspension Concentrations

Figure 25. (Left) Walker 256 cell concentration right after injection. (Right) There is a decrease in
cell number after injection through the 28G and 22G syringes compared to control values except for
the 22G syringe with 1.25M cells/ 25µL concentration.
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Figure 26. Cell concentration over time for the 2.5M cells/ 25µL injected concentration. Control (blue) shows
highest initial cell concentration of 2.9M cells. Control has the lowest exponential growth rate of 0.5M/day. 28G
needle (red) shows the lowest initial cell concentration of 1.6M cells, but has the highest exponential growth rate
of 0.9M/day. 22G needle (green) shows median initial cell concentration of 2.3M cells and has the median
exponential growth rate of 0.56M/day. Superimposed are fitting exponential trend lines of the data. M=1x10 6cells

Figure 27. Cell concentration over time for the1.25M cells/ 25µL injected concentration. Control (blue) and
22G needle show highest initial cell concentration of 1.3M cells and 1.6M cells, respectively. Control has the
median exponential growth rate of 0.7M/day. 28G needle (red) shows the lowest cell concentration of 1.05M
cells, but has the highest exponential growth rate of 0.85M/day. 22G has the median exponential growth rate
of 0.56M/day. Superimposed are fitting exponential trend lines of the scatter data. M=1x10 6cells
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3.2.4 Conclusions of cell viability test: The ~4% cell death after injection using the 28G
syringe and 2.5M cells/ 25µL concentration was likely caused by the high cell density and small
needle inner diameter. The decrease of cell quantity injected with the 28G needle (Fig. 25)
suggests that cells are attaching rapidly to the syringe/needle wall or clumping together at the
needle opening. This decrease is relevant as the number of cells being delivered into the rat tibia
is smaller than expected. The 22G needle with 1.25M cells/ 25µL concentration showed no
decrease in cell number compared to control; thus the 22G syringe needle will inject a greater
number of live cells compared to the 28G needle.
Overall, a larger needle inner diameter and lower cell concentration will provide the
greatest cell viability and delivery, as seen in the combination of 22G needle and 1.25M
cells/25µL. However, considering other factors such as bone destruction caused by the needle as
well as the restricted space inside the tibia, a 24G needle will be used in future experiments.

3.3 Improvement of cancer cell inoculation surgical technique
Injection of cancer cells into the tibia medullary cavity by direct injection is a complex
process. The cells need to be inoculated in the core of the medullary canal a few millimeters
below the growth plate. The difficulty in accessing the proximal tibia reduces the probability of
localized tumor formation. Arthrotomy is a commonly used technique that entitles the
dislocation of the knee to improve access into the knee joint. The inoculation requires the
detachment and displacement of the knee cap (without tearing the patellar ligament) and
surrounding tissue for the needle to be inserted at the intercondylar eminence at the proper angle
(Stepensky et al., 2002), to pierce perpendicular to the bone surface (Kurth et al., 2000). To
implement this procedure, a small rostro caudal 1 to 1.5 cm superficial incision will be made
along the lateral collateral ligament avoiding deep cuts to prevent injury (Mao-Ying et al., 2006).
With the small incision in place and making sure that ligaments and tendons are aside while
maintaining the leg in a straightened position, a scalpel will be used to separate the knee cap
from the femur via a single cut to avoid collateral tissue damage. Maintaining the leg unbent and
using low pressure, the knee cap will be pushed medially, until the dislocation takes place. Once
the knee cap is dislocated, the leg can be flexed and twisted to expose the tibia head.
By avoiding the meniscus, the 24G needle can pierce through the cartilage and bone. Using a
slow drilling motion of the needle (without removing the stylet to prevent clothing), the needle
40

will be inserted 5 to 7 mm below the knee joint into the medullary canal (Mao-Ying et al., 2006).
Prior to W256 cell injection, the stylet will be removed and an empty syringe will be connected
to the 24G needle to remove some marrow to create an empty space for the W256 cells. After
that, the syringe with marrow will be removed and the 24G needle will be connected to a glass
syringe containing 1.25x106 W256 cells per 25 μL. The cell suspension will be injected and the
needle will be maintained in the bone to prevent cell suspension egress. After 1 to 2 min the 24G
needle will be removed. The injection site will be closed with bone wax and veterinarian glue.
Even though this surgical technique is more invasive than the direct injection previously
described, the benefits of this technique overpass its risks. This surgical technique will be used in
future experiments to increase the tumor formation success rate.

3.4 Use of tumor-bearing tibiae as controls
In our pilot study, controls were the contralateral, unloaded tibiae that had not received
cancer cell inoculation. This control group lacked the injury caused by the needle, the tumor
formation, and the bone destruction caused by tumor growth. Therefore, non-inoculated tibias
are not proper samples for comparison. Consequently, controls will be rats with developed
tumors after cancer-cell injections that are not subjected to mechanical loading.
3.5 From 2D to 3D: microPET imaging
Even though our preliminary results using gamma camera imaging are promising, a more
sensitive, more specific and more easily quantifiable system is needed. In future studies we will
use microPET, which can improve all the above mentioned parameters that the gamma camera
does not have.
PET is now a widely used imaging modality in cancer (Zanzonico, 2004) particularly for
staging, and monitoring response after therapy (Martinez, 2008). Compared to single-photon
(planar and SPECT) imaging, PET provide greater quantitative accuracy, better spatial
resolution, and higher sensitivity. Clinically, PET has a lower incidence of false positives
compared to SPECT in bone metastases (18F-FDG vs. 99mTc-MDP or 99mTc-HMDP) (Ito et al.,
2007).
PET works on the theory of annihilation coincidence detection (ACD) of two collinear
511KeV gamma rays formed by the annihilation of a positron and negatron (Zanzonico, 2004;
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Martinez et al., 2008) (Fig. 28). True coincidences are accounted as pair annihilation; however,
there exist random and accidental events that reduce the image quality. The type of isotope used,
detector material and configurations, time windows of detection, computer processing power and
other mechanisms can be used to improve the system performance, sensitivity and spatial
resolution (Zanzonico, 2004; Martinez et al., 2008).

Figure 28. Positron (β+)
emitting radionuclides have
structurally unstable nuclei due
to a deficiency of neutrons (or
excess of protons) that approach
stability through the conversion
of a proton (p) into a neutron (n)
and emission of a positron
electron (e+
When the positron (e+) comes to
rest in the surrounding, usually
within several millimeters or less of the site of emission, it interacts electrostatically with an orbital
electron (e-) of an atom in the surrounding tissue. The positron and electron annihilate each, converting
their rest mass energies to electromagnetic radiation and thus emitting two 511-keV γ-rays back to back,
which are detected by the coincidence circuitry of the PET scanner. From Zanzonico, 2004; equation
from Martinez et al., 2008.

Characterization of lytic, sclerotic and mixed lesions of prostate cancer with metastases
to bone has been performed using microPET in mice (Hsu, et al., 2008), where scans of 18F-FDG
and 18F-fluoride were useful to differentiate between sclerotic and lytic lesions. PET has been
used with 18F-FDG and 18F-fluoride as a cocktail. This method showed an enhanced detection of
bone cancer (Iagaru et al., 2008). Morphologic and metabolic analyses have also been used with
PET and bone cancer using 18F-fluoride (Kawaguchi et al., 2010), in addition to histological
responses to chemotherapy using 18F-FDG (Dutour et al., 2009), and measurements of cellular
proliferation using 18F-FDG and 18F-fluoride (Arvanitis et al., 2008).
3D microPET imaging instead of gamma camera planar scans used in our preliminary
study will provide higher spatial resolution, 3D quantifiable images of drug distribution, and the
possibility to use other radiotracers such as 18F-FDG, 18F-fluoride and 89Zr-Herceptin. We have
performed a trial imaging protocol using the small animal PET scanner at MSKCC with 18Ffluoride, and bone is clearly delineated (Fig. 29).
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18F-fluoride 3D
reconstruction

Right
tibia
ROI
Right
tibia
ROI

18F-fluoride 3D
reconstruction

Figure 29. Small animal PET images of a rat
lower body. Left: Hemibody 3D projection.
Right: Coronal view slice demonstrating a
region of interest (ROI) of the tibia (dashed
lines). 3D volumes of interest were created over
contiguous tomographic sections to yield
volumetric activity data.

3.6 Herceptin as the new injected drug
Herceptin, also known as trastuzumab, is a human epidermal receptor (HER2/neu)
monoclonal antibody (Robert and Favret, 2007; Gutierrez and Schiff, 2011) approved by the
FDA. Herceptin is used in patients suffering from cancer that overexpresses the HER receptor.
HER2 receptor is associated with signal transduction pathways involving cell survival and
growth (Robert and Favret, 2007; Gutierrez and Schiff, 2011). A clinical trial of Herceptin in
patients suffering from metastatic breast cancer showed an improvement on the progression-free
survival rate (50% vs. 30% (p<0.01); Robert and Favret, 2007).
Herceptin has been used in nuclear medicine as an inmunoPET imaging tracer (Dijkers et
al., 2009; Holland et al., 2010). Herceptin can be radiolabel with 89Zr, and in vivo distribution of
89

Zr-labeled trastuzumab has been measured in healthy and tumor tissue in mice (Dijkers et al.,

2009; Holland et al., 2010). 89Zr-labeled trastuzumab can be radiolabeled in a stable manner;
systemic blood and tissue clearance is fast. Tumor uptake is slow when compared to small
tracers, but it increases greatly over time.
For our future work, Herceptin will be used with W256 cells. Herceptin was chosen
because of its clinical significance as well as its relatively large size (~145 kDa), which should
enable enhanced convection due to loading without binding in the Walker 256 tumor model
(Flessner et al., 2005). Given that W256 do not express HER receptors (Blouin et al., 2005),
Herceptin can be used as a non-specific radiotracer. The effects of mechanical deformation
should have a greater enhancement for larger molecules compared to smaller ones such as
pamidronate used in the preliminary study.
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3.7 High resolution microCT and histology to assess bone tumors
While the in vivo microCT scanner is effective for visualizing the developing tumor, it
does not have sufficient resolution to accurately assess the volume of the tumors and the effects
on the bone microarchitecture.
Guidelines for high-resolution micro-computed tomography assessment in small animal
models of bone have been given in several research articles such as Bouxsein et al. (2010). Using
these guides a scanning, reconstruction and analysis protocol has been developed for use in
future experiments to assess bone tumors after sacrifice.
Harvested tibiae containing tumors will be scanned using a Skyscan 1172 microCT
scanner (Skyscan, Belgium). Attenuation corrections will be performed according to the power
setting to be used by means of bright and dark field calibrations to air x-ray attenuation. Scans
will be completed within a low-attenuation-plastic holder filled with PBS. Nominal isotropic
voxel resolution of about ~1-4 μm will be used. Short step degrees, multiple averages and filters
can be used to improve the signal to noise ratio.
Through image processing the x-ray projections will be reconstructed into 8 bit bmp or
18 bit tiff images. Compensations for misalignment, ring artifacts, and beam hardening will be
completed to increase image quality. Hydroxyapatite rods (2 mm diameter, densities of 0.25 and
0.75 g/cm³) will also be scanned to obtain tissue mineral density (TMD). Measurements such as
BMD, trabecular and cortical porosity (connectivity and volume), trabecular volume, trabecular
and cortical surface area, trabecular connectivity, moments of inertia, trabecular and cortical
thickness, trabecular length and spacing, and degree of anisotropy will be calculated.
In addition to high resolution microCT, histology will be used as another tool for
assessment of tumor morphology, type and volume. Histology can provide detailed information
on the morphological local effects on drug delivery, correlations between drug uptake and tumor
type (sclerotic, lytic or mixed) and the effects of tumor volume on drug distribution. Histological
analysis of the tumors will be performed using plastic and paraffin-embedding with H&E to
quantify tumor morphology and pathology.

3.8 Summary of planned experiments
Using the improvements described above, the next set of experiments will more
completely assess whether mechanical loading can enhance drug delivery to bone tumors.
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Briefly, our planned experiments include the following: quantification of the effectiveness of
mechanically facilitated delivery of therapeutic agents on tumors using 18F-FDG, 18F-fluoride
and 89Zr-labeled Herceptin. 18F-fluoride will be used to image drug uptake into the bone tumor
extracellular matrix, 18F-FDG will be used to quantify uptake into the bone tumor cells and 89ZrHerceptin will be used to assess non-specific convective drug delivery. Because of the short half
life (~100min) of 18F, 18F-fluoride and 18F-FDG can be imaged consecutively as long as previous
activity has decayed.
Drug uptake into rat bone tumors will be quantified after mechanical load application
using the non-invasive loading device (Table 4). A time line will be implemented as follows
(Table 3):
Time Line
Day = 0
Day = 1
Day = 21
Day = 29

Day = 30-31

Action
Walker 256 cell culturing process (~2 week process)
Intra-tibial injections of cancer cells (1 day process)
MicroCT scans (confirmation of tumor-related lesions)
-Tail-injections of 18F-fluoride and 18F-FDG*
-No mechanical loading (Time point 1)
-3D microPET scans(used as reference uptake values)
plus
-Tail-injections of 89Zr-Herceptin
-No mechanical loading (control group)
-3D microPET scans
-Animal sacrifice and tissue harvesting
-Tail-injections of 18F-fluoride and 18F-FDG*
-Mechanical loading (Time point 2)
-3D microPET scans(experimental values)
plus
-Tail-injections of 89Zr-Herceptin
-Mechanical loading (experimental group)
-3D microPET scans
-Animal sacrifice and tissue harvesting

Day = 57

a) Dose calibrator measurements
b) Scintillation counter measurements
Onward
Imaging analysis
Table 3. Time line of improved experiments. * 18F-fluoride and 18F-FDG can be used in sequential scans
given to the short half life of the tracer.
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Summary of
Proposed
Experiments

Animal

Num 1st Tracer 1st Imaging 2ndTracer Mechanical
ber
injection
injection Loading noninvasive

18

F-fluoride

Female
Sprague
Dawley rat
with Walker
256 bone tumor
Female
Sprague
18
F-FDG
Dawley rat
with Walker
256 bone tumor
Female
Sprague
89
Zr-Herceptin
Dawley rat
with Walker
256 bone tumor
Female
Sprague
89
Zr-Herceptin
Dawley rat
with Walker
256 bone tumor

18

12

Ffluoride

12

18

microPET

F-FDG microPET

18

Ffluoride

Tibia (800
microstrain at
1 Hz for 600
cycles)

2nd Imaging Loading
(mechanically Sessions
enhanced
value)

microPET

1

Tibia, (800
microstrain at
1 Hz for 600
cycles)

microPET

1

Tibia (800
Zrmicrostrain at
Herceptin 1 Hz for 600
cycles)

microPET

1

microPET

0

18

F-FDG

89

12

N/A

N/A

12

N/A

N/A

89

ZrHerceptin

N/A

Table 4. Experimental set up for specific aim 1. N/A= non-applicable.

3.9 Translation to the clinic: Positive results using this approach could enhance the
treatment of bone tumors, resulting in an improvement in the quality of life for patients suffering
from bone metastasis. Future studies are planned to address the long-term goal of developing a
clinical protocol that uses load-bearing exercise, e.g., slow treadmill walking or stationary
bicycling, as a new chemotherapy and or immunotherapy treatment adjunct. This low-risk and
easy-to-implement approach may enhance a drug’s clinical effect while potentially decreasing
systemic drug dosage and unwanted side effects.
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